Archive
-
2021/05/09Furmonertinib added to Qindao e-Insurance coverage rolled out on Mother’s Day
-
2021/05/08Furmonertinib included in the freshly updated Chengdu Supplemental Medical Insurance Catalog
-
2021/04/30Furmonertinib Incorporated into Linyi Medicare Catalogue
-
2021/04/30Allist employees insured under the Shanghai new supplemental medical insurance plan
-
2021/04/24Furmonertinib covered by Zhoushan Supplemental Medical Insurance Program
-
2021/04/18National Kick-off Meeting for FORWARD, a Study Evaluating Furmonertinib as Adjuvant Therapy, Successfully Held
-
2021/04/10Innovation for the Future, Molecules Change the World: Allist Invited to Join China Pharmaceutical Innovation 100 Union
-
2021/04/08Allist makes it into the top 10 listed biopharmaceutical companies in 2020
-
2021/03/27Allist’s Clinical Study (Phase IIb) on Furmonertinib Published in Full on The Lancet Respiratory Medicine
-
2021/03/24The charitable Furmonertinib patient assistance program launched